MesoCancerVac is under clinical development by Amphera and currently in Phase II for Malignant Mesothelioma. According to GlobalData, Phase II drugs for Malignant Mesothelioma have a 42% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how MesoCancerVac’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

MesoCancerVac overview

MesoCancerVac is under development for the treatment of pancreatic adenocarcinoma, malignant pleural mesothelioma, metastasized pancreatic ductal adenocarcinoma and peritoneal mesothelioma. It is administered through intravenous and intradermal routes. The therapy uses the autologous dendritic cells pulsed with allogeneic tumour cell lysates (fragments of tumor cells). Dendritic cells (DCs) possess the ability to stimulate antigen specific T cell.

Amphera overview

Amphera B.V., is a biotechnology company that focused on developing an immunotherapy for mesothelioma. The company is headquartered in The Netherlands.

For a complete picture of MesoCancerVac’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.